It is worth noticing that both, reduced levels of soluable SorLA [189] as well increased levels of soluable SorLA [190] have been detected in CSF of AD patients. Altogether, these findings propose that SorLA may critically influence amyloidogenic events underlying the AD pathology and nominate the receptor as a potential target for the therapeutic interventions. The gene discussed is SORL1; the disease is Alzheimer disease.